First-Line Treatment of Advanced or Metastatic Gallbladder Cancer with ECOG Performance Status 2

Selecting first-line systemic therapy for advanced or metastatic gallbladder carcinoma requires careful consideration of functional status. Patients with an ECOG performance status of 2 — or other factors of fragility — represent a specific subgroup for whom the treatment approach differs from those with better performance status.

Clinical Scenario

Advanced or metastatic gallbladder carcinoma in a patient with ECOG performance status 2. This level of functional limitation is a key determinant in first-line therapy selection and may prompt consideration of a less intensive regimen.

Treatment Approach (Partial Overview)

First-line therapy in this setting centres on a single-agent systemic regimen. The full selection rationale, specific agent, and clinical criteria are available in the complete structured protocol.

Monitoring Goals

Treatment efficacy is assessed by imaging (CT or MRI) at regular intervals of 8–12 weeks, or earlier if disease-related complications arise. Tumour markers CA 19-9 or CEA may also be followed when known to be elevated at baseline.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2022.10.506

Gemcitabine monotherapy may be used in patients with a PS of 2.

Gemcitabine monotherapy may be preferred in patients with a PS of 2 or other factors of fragility.

During systemic and locoregional therapy for advanced disease, follow-up should be conducted at a frequency of 8-12 weeks to allow best assessment of treatment efficacy, or as required for disease-related complications.

In addition to imaging by CT or MRI, CA 19-9 or carcinoembryonic antigen (CEA) levels may be used to monitor the course of the disease if one or both are known to be secreted.

View source ↗